JOTROL
Phase 2- Indications
- Mucopolysaccharidoses Type 1, Friedreich's Ataxia, MELAS, Mild Cognitive Impairment, Early Alzheimer's Disease
Company intelligence / Profile preview
EMA Wellness
Norwood, Massachusetts, USAemawellness.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
EMA Wellness provides a unified eCOA, analytics, and adjudication platform for clinical trials, focusing on data integration and real-time visualization.
- Therapeutic areas
- Psychiatry
- Modalities
- Digital health toolsAI algorithms
- Industry
- Biomedical IT and Biomedical Data Platforms
02
Drug pipeline
1 asset03
Partnerships
Pharmaceutical sponsorsCROspayers
Beyond the preview
Go deeper on EMA Wellness.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EMA Wellness.